TN2010000136A1 - Composition comprising sphingosine 1 phosphate (s1p) receptor modulators - Google Patents

Composition comprising sphingosine 1 phosphate (s1p) receptor modulators

Info

Publication number: TN2010000136A1
Authority: TN; Tunisia
Prior art keywords: sphingosine; phosphate; receptor modulators; composition; amino
Prior art date: 2007-10-12

Application number

TNP2010000136A

Other languages

English (en)

Inventor

Colleen Ruegger

Michael Ambuhl

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-12

Filing date

2010-03-26

Publication date

2011-09-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40032615&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2010000136(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-03-26 Application filed by Novartis Ag filed Critical Novartis Ag

2011-09-26 Publication of TN2010000136A1 publication Critical patent/TN2010000136A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Inorganic Chemistry (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Zoology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Botany (AREA)
Biotechnology (AREA)
Alternative & Traditional Medicine (AREA)
Medical Informatics (AREA)
Natural Medicines & Medicinal Plants (AREA)
Microbiology (AREA)
Mycology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Virology (AREA)
Hospice & Palliative Care (AREA)

TNP2010000136A 2007-10-12 2010-03-26 Composition comprising sphingosine 1 phosphate (s1p) receptor modulators TN2010000136A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US97948207P	2007-10-12	2007-10-12
PCT/US2008/079264 WO2009048993A2 (fr)	2007-10-12	2008-10-09	Compositions comprenant des modulateurs du récepteur de sphingosine 1-phosphate (s1p)

Publications (1)

Publication Number	Publication Date
TN2010000136A1 true TN2010000136A1 (en)	2011-09-26

Family

ID=40032615

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2010000136A TN2010000136A1 (en)	2007-10-12	2010-03-26	Composition comprising sphingosine 1 phosphate (s1p) receptor modulators

Country Status (33)

Country	Link
US (6)	US8673918B2 (fr)
EP (7)	EP2653154A1 (fr)
JP (2)	JP6034000B2 (fr)
KR (3)	KR101710845B1 (fr)
CN (1)	CN101820916A (fr)
AR (1)	AR068986A1 (fr)
AU (1)	AU2008310846C1 (fr)
BR (1)	BRPI0818161B8 (fr)
CA (2)	CA2699788C (fr)
CL (1)	CL2008003003A1 (fr)
CO (1)	CO6270342A2 (fr)
DK (1)	DK2952177T3 (fr)
EC (1)	ECSP10010169A (fr)
ES (2)	ES2864671T3 (fr)
HK (1)	HK1213768A1 (fr)
HR (1)	HRP20150838T1 (fr)
HU (2)	HUE053835T2 (fr)
IL (3)	IL204514B (fr)
JO (2)	JOP20080436B1 (fr)
MA (1)	MA31799B1 (fr)
MX (1)	MX337152B (fr)
MY (1)	MY159358A (fr)
NZ (1)	NZ600355A (fr)
PE (2)	PE20130309A1 (fr)
PL (2)	PL2952177T3 (fr)
PT (2)	PT2952177T (fr)
RU (1)	RU2010118457A (fr)
SG (2)	SG187458A1 (fr)
SI (2)	SI2952177T1 (fr)
TN (1)	TN2010000136A1 (fr)
TW (1)	TW200927142A (fr)
WO (1)	WO2009048993A2 (fr)
ZA (1)	ZA201001819B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8785484B2 (en)	2008-03-17	2014-07-22	Actelion Pharmaceuticals Ltd	Dosing regimen for a selective S1P1 receptor agonist
CN103271905A (zh) *	2008-08-18	2013-09-04	诺瓦提斯公司	用于治疗周围神经病的化合物
BRPI0923213A2 (pt)	2008-12-22	2016-01-26	Novaris Ag	regime de dosagem de um agonista do receptor para s1p.
MX2011006623A (es) *	2008-12-22	2011-07-12	Novartis Ag	Regimen de dosificacion para un agonista de los receptores de s1p.
EA201291096A1 (ru) *	2010-04-22	2013-04-30	Рациофарм Гмбх	Финголимод в форме твердого раствора
US20130102683A1 (en) *	2010-04-22	2013-04-25	Ratiopharm Gmbh	Melt-granulated fingolimod
CN101973898B (zh) *	2010-09-09	2013-06-19	南京明生医药技术有限公司	2-对辛基苯乙基-2-氨基丙二醇衍生物及其应用
EA026144B9 (ru) *	2011-01-07	2021-10-26	Новартис Аг	Твердофазная фармацевтическая композиция, содержащая гемифумаратную соль 1-{4-[1-(4-циклогексил-3-трифторметилбензилоксиимино)этил]-2-этилбензил}азетидин-3-карбоновой кислоты, и таблетка, ее содержащая
WO2012095853A1 (fr)	2011-01-10	2012-07-19	Novartis Pharma Ag	Formulations à libération modifiée comprenant des modulateurs des récepteurs sip
ES2388273B1 (es) *	2011-03-16	2013-10-01	Consejo Superior De Investigaciones Científicas (Csic)	Uso de inhibidores de receptores de s1p para el tratamiento de la estenosis aórtica calcificada
AR085749A1 (es) *	2011-04-01	2013-10-23	Novartis Ag	Formulaciones
WO2013019872A1 (fr)	2011-08-01	2013-02-07	Teva Pharmaceutical Industries Ltd.	Procédé de préparation de compositions pharmaceutiques comprenant du fingolimod
US20150218090A1 (en) *	2011-10-21	2015-08-06	Novartis Ag	Dosage regimen for an s1p receptor modulator or agonist
WO2013091704A1 (fr)	2011-12-22	2013-06-27	Synthon Bv	Composition pharmaceutique comprenant le fingolimod
RU2482842C1 (ru) *	2012-04-26	2013-05-27	Открытое акционерное общество "Новосибхимфарм"	Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) *	2012-06-13	2014-02-20	Открытое акционерное общество "Новосибхимфарм"	Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
RU2496486C1 (ru) *	2012-07-11	2013-10-27	Александр Васильевич Иващенко	Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
JP2014129238A (ja) *	2012-12-28	2014-07-10	Lion Corp	エトドラク含有固形製剤
WO2014141298A2 (fr) *	2013-03-11	2014-09-18	Astron Research Limited	Composition pharmaceutique stable de fingolimod
EP2996681B1 (fr) *	2013-05-13	2019-12-18	Synthon B.V.	Composition pharmaceutique contenant du fingolimod
JP6316422B2 (ja) *	2013-07-29	2018-04-25	アイザントドラッグリサーチソリューションズプライベートリミテッドＡｉｚａｎｔＤｒｕｇＲｅｓｅａｒｃｈＳｏｌｕｔｉｏｎｓＰｖｔＬｔｄ	フィンゴリモドの医薬組成物
US20150141520A1 (en) *	2013-11-18	2015-05-21	Chandrasekhar Kandi	Stabilized pharmaceutical compositions of fingolimod and process for preparation thereof
US9493442B2 (en)	2014-02-13	2016-11-15	Incyte Corporation	Cyclopropylamines as LSD1 inhibitors
ME03580B (fr)	2014-02-13	2020-07-20	Incyte Corp	Cyclopropylamines en tant qu'inhibiteurs de lsd1
AU2015217073B2 (en)	2014-02-13	2019-08-22	Incyte Holdings Corporation	Cyclopropylamines as LSD1 inhibitors
US9527835B2 (en)	2014-02-13	2016-12-27	Incyte Corporation	Cyclopropylamines as LSD1 inhibitors
MX2016013236A (es) *	2014-04-10	2017-01-16	Novartis Ag	Formulacion inmunosupresora.
WO2016007736A1 (fr)	2014-07-10	2016-01-14	Incyte Corporation	Imidazopyrazines en tant qu'inhibiteurs de lsd1
WO2016007727A1 (fr)	2014-07-10	2016-01-14	Incyte Corporation	Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1
TWI687419B (zh)	2014-07-10	2020-03-11	美商英塞特公司	作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
US9695167B2 (en)	2014-07-10	2017-07-04	Incyte Corporation	Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
WO2016026461A1 (fr) *	2014-08-22	2016-02-25	Sunshine Lake Pharma Co., Ltd.	Composition solide de fingolimod et préparation associée
WO2016042493A1 (fr)	2014-09-19	2016-03-24	Aizant Drug Research Pvt. Ltd	Compositions pharmaceutiques de fingolimod
KR20170084086A (ko) *	2014-11-17	2017-07-19	아르노 테라퓨틱스 인코포레이티드	오나프리스톤 연장-방출 조성물 및 방법
WO2016118515A1 (fr) *	2015-01-20	2016-07-28	Handa Pharmaceuticals, Llc	Forme galénique solide stable de fingolimod
US9925138B2 (en)	2015-01-20	2018-03-27	Handa Pharmaceuticals, Llc	Stable solid fingolimod dosage forms
EP3277689B1 (fr)	2015-04-03	2019-09-04	Incyte Corporation	Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
US10583087B2 (en) *	2015-04-28	2020-03-10	Astellas Pharma Inc.	Pharmaceutical composition for oral administration
PE20181175A1 (es)	2015-08-12	2018-07-20	Incyte Corp	Sales de un inhibidor de lsd1
RU2639424C2 (ru) *	2015-09-15	2017-12-21	Закрытое Акционерное Общество "Биокад"	Твердая пероральная фармацевтическая композиция S1P-агониста или его фармацевтически приемлемой соли, способы ее получения и способы лечения и снижения частоты клинических обострений рассеянного склероза
BR112018006648A2 (pt) *	2015-10-02	2018-10-23	Mylan Inc.	formulações estáveis de fingolimode
AU2017252328B2 (en) *	2016-04-22	2023-02-23	Incyte Corporation	Formulations of an LSD1 inhibitor
US11434200B2 (en)	2017-03-09	2022-09-06	Novartis Ag	Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11629124B2 (en)	2017-03-09	2023-04-18	Novartis Ag	Solid forms comprising an oxime ether compound, compositions and methods of use thereof
WO2018178744A1 (fr)	2017-03-29	2018-10-04	Deva Holding Anonim Sirketi	Formulations stables de fingolimod
JP7365409B2 (ja)	2018-06-28	2023-10-19	エイアールエックスエルエルシー	溶解性単位用量膜構造物を製造するための分配方法
US10968200B2 (en)	2018-08-31	2021-04-06	Incyte Corporation	Salts of an LSD1 inhibitor and processes for preparing the same
CN112805241A (zh)	2018-10-05	2021-05-14	富士化学工业株式会社	多孔二氧化硅颗粒组合物
WO2022220593A1 (fr) *	2021-04-14	2022-10-20	주식회사 엘지화학	Composition pharmacologique directement compressible comprenant un agoniste du récepteur de sphingosine-1-phosphate
WO2024126409A1 (fr)	2022-12-12	2024-06-20	Synthon B.V.	Composition pharmaceutique contenant du siponimod

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2579602B2 (ja) *	1992-10-21	1997-02-05	吉富製薬株式会社	２−アミノ−１，３−プロパンジオール化合物および免疫抑制剤
PT778263E (pt)	1994-08-22	2002-06-28	Mitsubishi Pharma Corp	Composto de benzeno e sua utilizacao farmaceutica
US5616621A (en) *	1995-01-30	1997-04-01	American Home Products Corporation	Taste masking liquids
SI0812588T1 (en)	1995-12-28	2005-02-28	Mitsubishi Pharma Corporation	Pharmaceutical external preparations for topical administration comprising 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol for the treatment of diseases induced from immune disorder
JP4153563B2 (ja)	1997-02-27	2008-09-24	ノバルティスアーゲー	医薬組成物
EP1002792B1 (fr)	1997-04-04	2004-07-14	Mitsubishi Pharma Corporation	Composes 2-aminopropane-1,3-diol, leur utilisation pharmaceutique, et intermediaires servant a leur synthese
JP4627356B2 (ja)	1999-06-30	2011-02-09	松森　　昭	ウイルス性心筋炎の予防または治療薬剤
MXPA03000397A (es)	2000-07-13	2003-05-27	Sankyo Co	Derivados de aminoalcohol.
EP1315735A4 (fr)	2000-08-31	2005-04-06	Merck & Co Inc	Derives de phosphates utilises en tant qu'agents immuno-regulateurs
JP2002316985A (ja)	2001-04-20	2002-10-31	Sankyo Co Ltd	ベンゾチオフェン誘導体
PT1431284E (pt)	2001-09-27	2008-01-21	Kyorin Seiyaku Kk	Derivado de sulfureto de diarilo, um seu sal de adição e imunossupressor
CA2460640C (fr)	2001-09-27	2011-03-29	Kyorin Pharmaceutical Co., Ltd.	Derives d'ether de diaryle, ses sels et agents immunosuppresseur utilisat ces derives
AU2003207567B2 (en)	2002-01-18	2008-01-24	Merck Sharp & Dohme Corp.	Edg receptor agonists
AU2003202994B2 (en)	2002-01-18	2007-11-22	Merck Sharp & Dohme Corp.	N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
CN1312125C (zh)	2002-09-19	2007-04-25	杏林制药株式会社	氨基醇衍生物及其加成盐以及免疫抑制剂
DE602004032118D1 (de)	2003-02-18	2011-05-19	Kyorin Seiyaku Kk	Aminophosphonsäurederivate, deren additionssalze und s1p-rezeptormodulatoren
EP2319502A1 (fr)	2003-04-08	2011-05-11	Novartis AG	Composition orale solide comportant un agoniste de récepteur S1P et alcool de sucre
TW200503783A (en)	2003-04-11	2005-02-01	Altana Pharma Ag	Oral pharmaceutical preparation for proton pump antagonists
FR2854549B1 (fr)	2003-05-06	2005-06-24	Actis Ets	Tete pour l'equipement d'un bras de robot destine a realiser une operation d'ebavurage ou de cardage
TW200505442A (en)	2003-05-19	2005-02-16	Genomics Inst Of The Novartis Res Foundation	Immunosuppressant compounds and compositions
MY150088A (en) *	2003-05-19	2013-11-29	Irm Llc	Immunosuppressant compounds and compositions
US7838562B2 (en)	2003-06-24	2010-11-23	University Of Connecticut	Methods of inhibiting vascular permeability and apoptosis
BRPI0413151A (pt)	2003-08-28	2006-10-03	Novartis Ag	derivados de amino propanol
JP4861177B2 (ja)	2003-09-12	2012-01-25	ニューロノバエービー	神経系の障害の処置
UA74941C2 (en)	2004-04-26	2006-02-15	Fos Internat S A	A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (fr)	2004-05-05	2005-12-01	Adler, Richard, S.	Systemes et techniques de protection d'un bateau contre des attaques en surface ou sous l'eau
GB0504544D0 (en)	2005-03-04	2005-04-13	Novartis Ag	Organic compounds
US8633161B2 (en)	2005-03-24	2014-01-21	The Ohio State University Research Foundation	Therapeutic agents for the treatment of leukemia
CN1891212B (zh) *	2005-07-07	2010-10-13	马启明	一种口服制剂及其制备方法
GT200600350A (es) *	2005-08-09	2007-03-28		Formulaciones líquidas
ES2748432T3 (es) *	2006-09-26	2020-03-16	Novartis Ag	Composiciones farmacéuticas que comprenden un modulador de S1P

2008
- 2008-10-09 DK DK15173766.5T patent/DK2952177T3/da active
- 2008-10-09 EP EP13177175.0A patent/EP2653154A1/fr not_active Withdrawn
- 2008-10-09 JP JP2010529013A patent/JP6034000B2/ja active Active
- 2008-10-09 PL PL15173766T patent/PL2952177T3/pl unknown
- 2008-10-09 ES ES15173766T patent/ES2864671T3/es active Active
- 2008-10-09 PT PT151737665T patent/PT2952177T/pt unknown
- 2008-10-09 PL PL12155251T patent/PL2465492T3/pl unknown
- 2008-10-09 US US12/682,343 patent/US8673918B2/en not_active Expired - Fee Related
- 2008-10-09 CA CA2699788A patent/CA2699788C/fr active Active
- 2008-10-09 SI SI200832164T patent/SI2952177T1/sl unknown
- 2008-10-09 KR KR1020167004264A patent/KR101710845B1/ko active IP Right Grant
- 2008-10-09 EP EP12155251.7A patent/EP2465492B1/fr not_active Revoked
- 2008-10-09 AR ARP080104420A patent/AR068986A1/es not_active Application Discontinuation
- 2008-10-09 EP EP16182588.0A patent/EP3120833A1/fr not_active Withdrawn
- 2008-10-09 CA CA2925175A patent/CA2925175A1/fr not_active Abandoned
- 2008-10-09 JO JOP/2008/0436A patent/JOP20080436B1/ar active
- 2008-10-09 KR KR1020177004540A patent/KR20170021904A/ko not_active Application Discontinuation
- 2008-10-09 ES ES12155251.7T patent/ES2545361T3/es active Active
- 2008-10-09 EP EP20176935.3A patent/EP3733162A1/fr not_active Withdrawn
- 2008-10-09 MX MX2010003925A patent/MX337152B/es active IP Right Grant
- 2008-10-09 SG SG2013002415A patent/SG187458A1/en unknown
- 2008-10-09 CN CN200880111160A patent/CN101820916A/zh active Pending
- 2008-10-09 AU AU2008310846A patent/AU2008310846C1/en active Active
- 2008-10-09 PT PT121552517T patent/PT2465492E/pt unknown
- 2008-10-09 TW TW097139107A patent/TW200927142A/zh unknown
- 2008-10-09 SI SI200831476T patent/SI2465492T1/sl unknown
- 2008-10-09 WO PCT/US2008/079264 patent/WO2009048993A2/fr active Application Filing
- 2008-10-09 EP EP15173766.5A patent/EP2952177B1/fr active Active
- 2008-10-09 BR BRPI0818161A patent/BRPI0818161B8/pt active IP Right Grant
- 2008-10-09 SG SG10201800085XA patent/SG10201800085XA/en unknown
- 2008-10-09 RU RU2010118457/15A patent/RU2010118457A/ru unknown
- 2008-10-09 EP EP20176933.8A patent/EP3733161A1/fr not_active Withdrawn
- 2008-10-09 HU HUE15173766A patent/HUE053835T2/hu unknown
- 2008-10-09 HU HUE12155251A patent/HUE027696T2/en unknown
- 2008-10-09 EP EP08838495A patent/EP2209493A2/fr not_active Withdrawn
- 2008-10-09 KR KR1020107010336A patent/KR101600098B1/ko active Application Filing
- 2008-10-09 NZ NZ600355A patent/NZ600355A/xx not_active IP Right Cessation
- 2008-10-09 MY MYPI2010001202A patent/MY159358A/en unknown
- 2008-10-10 PE PE2012002520A patent/PE20130309A1/es not_active Application Discontinuation
- 2008-10-10 CL CL2008003003A patent/CL2008003003A1/es unknown
- 2008-10-10 PE PE2008001756A patent/PE20090799A1/es not_active Application Discontinuation
2010
- 2010-03-15 ZA ZA2010/01819A patent/ZA201001819B/en unknown
- 2010-03-15 IL IL204514A patent/IL204514B/en active IP Right Grant
- 2010-03-26 TN TNP2010000136A patent/TN2010000136A1/fr unknown
- 2010-04-28 CO CO10050315A patent/CO6270342A2/es not_active Application Discontinuation
- 2010-04-30 MA MA32805A patent/MA31799B1/fr unknown
- 2010-05-11 EC EC2010010169A patent/ECSP10010169A/es unknown
- 2010-10-18 HK HK16101686.9A patent/HK1213768A1/zh unknown
2014
- 2014-01-27 US US14/164,623 patent/US20140142192A1/en not_active Abandoned
- 2014-12-04 JP JP2014246066A patent/JP2015091822A/ja active Pending
2015
- 2015-02-25 US US14/631,102 patent/US9399066B2/en not_active Expired - Fee Related
- 2015-08-06 HR HRP20150838TT patent/HRP20150838T1/hr unknown
2016
- 2016-06-15 US US15/183,523 patent/US20160296481A1/en not_active Abandoned
2017
- 2017-02-14 US US15/432,628 patent/US20170151195A1/en not_active Abandoned
- 2017-09-08 US US15/698,742 patent/US20170368001A1/en not_active Abandoned
- 2017-11-19 IL IL255737A patent/IL255737B/en active IP Right Grant
2020
- 2020-10-13 IL IL277999A patent/IL277999A/en unknown
2021
- 2021-07-08 JO JOP/2021/0187A patent/JOP20210187A1/ar unknown

Also Published As

Publication number	Publication date
PT2465492E (pt)	2015-10-15
DK2952177T3 (da)	2021-04-26
SG187458A1 (en)	2013-02-28
RU2010118457A (ru)	2011-11-20
HK1213768A1 (zh)	2016-07-15
CA2925175A1 (fr)	2009-04-16
NZ600355A (en)	2013-02-22
JOP20080436B1 (ar)	2023-03-28
BRPI0818161A2 (pt)	2017-05-16
SI2952177T1 (sl)	2021-07-30
US20140142192A1 (en)	2014-05-22
EP2952177A1 (fr)	2015-12-09
RU2016138157A3 (fr)	2020-02-10
WO2009048993A3 (fr)	2010-05-06
ECSP10010169A (es)	2010-06-29
PL2465492T3 (pl)	2015-11-30
EP2653154A1 (fr)	2013-10-23
SG10201800085XA (en)	2018-02-27
JP6034000B2 (ja)	2016-11-30
TW200927142A (en)	2009-07-01
CN101820916A (zh)	2010-09-01
KR20160025633A (ko)	2016-03-08
HUE053835T2 (hu)	2021-07-28
HUE027696T2 (en)	2016-10-28
CO6270342A2 (es)	2011-04-20
CA2699788A1 (fr)	2009-04-16
EP3733161A1 (fr)	2020-11-04
US9399066B2 (en)	2016-07-26
MX337152B (es)	2016-02-15
AU2008310846A1 (en)	2009-04-16
RU2016138157A (ru)	2018-12-13
ES2864671T3 (es)	2021-10-14
KR20170021904A (ko)	2017-02-28
PE20130309A1 (es)	2013-03-30
WO2009048993A2 (fr)	2009-04-16
KR20100091179A (ko)	2010-08-18
US8673918B2 (en)	2014-03-18
CL2008003003A1 (es)	2009-05-15
AU2008310846C1 (en)	2022-10-06
CA2699788C (fr)	2016-06-14
US20160296481A1 (en)	2016-10-13
HRP20150838T1 (hr)	2015-11-06
IL204514B (en)	2018-01-31
US20170151195A1 (en)	2017-06-01
KR101600098B1 (ko)	2016-03-04
EP3120833A1 (fr)	2017-01-25
ZA201001819B (en)	2010-12-29
MA31799B1 (fr)	2010-10-01
ES2545361T3 (es)	2015-09-10
EP2209493A2 (fr)	2010-07-28
US20170368001A1 (en)	2017-12-28
JP2015091822A (ja)	2015-05-14
AR068986A1 (es)	2009-12-23
SI2465492T1 (sl)	2015-12-31
US20150165046A1 (en)	2015-06-18
EP2465492B1 (fr)	2015-07-01
EP3733162A1 (fr)	2020-11-04
US20100267675A1 (en)	2010-10-21
PT2952177T (pt)	2021-04-26
EP2465492A1 (fr)	2012-06-20
MY159358A (en)	2016-12-30
PE20090799A1 (es)	2009-07-20
IL255737B (en)	2020-10-29
EP2952177B1 (fr)	2021-01-20
BRPI0818161B8 (pt)	2021-05-25
AU2008310846B2 (en)	2012-06-21
JOP20210187A1 (ar)	2023-01-30
MX2010003925A (es)	2010-05-05
IL277999A (en)	2020-11-30
IL255737A (en)	2018-01-31
JP2011500583A (ja)	2011-01-06
KR101710845B1 (ko)	2017-02-27
PL2952177T3 (pl)	2021-07-19
BRPI0818161B1 (pt)	2020-12-22

Publication	Publication Date	Title
TN2010000136A1 (en)	2011-09-26	Composition comprising sphingosine 1 phosphate (s1p) receptor modulators
UY32156A (es)	2010-04-30	Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones.
ECSP088854A (es)	2008-11-27	Moduladores bencimidazolicos de vr1
PH12013500365A1 (en)	2014-09-08	Anti-infective agents and uses thereof
MY148253A (en)	2013-03-29	Azaadamantane derivatives and methods of use
MX2010002902A (es)	2010-06-02	Pirimidinas anti-infecciosas y usos de las mismas.
BRPI0705546A (pt)	2008-08-12	composições de tratamento oral
SV2010003737A (es)	2011-03-15	Derivados de indazol sustituidos con fenilo y benzodioxinilo
MX2019012750A (es)	2020-02-03	Moduladores del receptor s1p para el tratamiento de esclerosis multiple.
TW200738641A (en)	2007-10-16	Pyrazole based LXR modulators
HK1154777A1 (en)	2012-05-04	Lipoprotein lipase-activating compositions comprising benzene derivatives
MX2009008324A (es)	2009-10-20	Compuestos 6´-sustituidos que tienen afinidad con el receptor de 5-hidroxitriptamina-6.
WO2012071212A3 (fr)	2013-04-04	Nouveaux acides phosphoniques utilisés comme modulateurs des récepteurs s1p
UY30356A1 (es)	2008-01-02	Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos.
BRPI0815455B8 (pt)	2020-12-01	compostos derivados de n-fenilacetamida, composição farmacêutica, composição cosmética, uso cosmético de uma composição, e usos de um composto do mesmo
TW200745048A (en)	2007-12-16	Novel benzimidazole and benzothiazole derivatives, preparation process therefor, application thereof as medicaments, pharmaceutical compositions and novel use especially as CMET inhibitors
TW200613317A (en)	2006-05-01	Steroid prodrugs with androgenic action
MX2009012683A (es)	2009-12-11	Benzamidas utiles como moduladores del receptor s1p.
SA112330437B1 (ar)	2015-07-01	تركيبات دوائية محتوية على عامل منوم او مخدر وطريقة تحضيرها
MX2009008704A (es)	2009-10-19	Metodos para corregir desequilibrio entre resorcion de huesos y formacion de huesos, equipos y composiciones para llevarlos a cabo.
GEP20084365B (en)	2008-05-13	Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions